|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Recurrence of choledocholithiasis following endoscopic bile duct clearance: Long term results and factors associated with recurrent bile duct stones显示文摘AIM To evaluate the rate of recurrence of symptomatic chol-edocholithiasis and identify factors associated with the recurrence of bile duct stones in patients who underwent endoscopic retrograde cholangiopancreatography(ERCP) and endoscopic sphincterotomy(EST) for bile duct stone disease.METHODS All patients who underwent ERCP and EST for bile duct stone disease and had their bile duct cleared from 1/1/2005 until 31/12/2008 was enrolled. All symptomatic recurrences during the study period(until 31/12/2015) were recorded. Clinical and laboratory data potentially associated with common bile duct(CBD) stone recurrence were retrospectively retrieved from patients' files.RESULTS A total of 495 patients were included. Sixty seven(67) out of 495 patients(13.5%) presented with recurrent symptomatic choledocholithiasis after 35.28 ± 16.9 mo while twenty two(22) of these patients(32.8%) experienced a second recurrence after 35.19 ± 23.2 mo. Factors associated with recurrence were size(diameter) of the largest CBD stone found at first presentation(10.2 ± 6.9 mm vs 7.2 ± 4.1 mm, P = 0.024), diameter of the CBD at the first examination(15.5 ± 6.3 mm vs 12.0 ± 4.6 mm, P = 0.005), use of mechanical lithotripsy(ML)(P = 0.04) and presence of difficult lithiasis(P = 0.04). Periampullary diverticula showed a trend towards significance(P = 0.066). On the contrary, number of stones, angulation of the CBD, number of ERCP sessions required to clear the CBD at first presentation, more than one ERCP session needed to clear the bile duct initially and a gallbladder in situ did not influence recurrence. CONCLUSION Bile duct stone recurrence is a possible late complication following endoscopic stone extraction and CBD clearance. It appears to be associated with anatomical parameters(CBD diameter) and stone characteristics(stone size, use of ML, difficult lithiasis) at first presentation. | Christos Konstantakis Christos Triantos Vasileios Theopistos Georgios Theocharis Ioannis Maroulis Georgia Diamantopoulou Konstantinos Thomopoulos | 2017 | World Journal of Gastrointestinal Endoscopy2017，9，1： | 46 |
| 2 | Inhibition of 12-lipoxygenase reduces proliferation and induces apoptosis of hepatocellular carcinoma cells in vitro and in vivo显示文摘BACKGROUND:12-lipoxygenase(12-LOX) has been reported to be an important gene in cancer cell proliferation and survival,and tumor metastasis.However,its role in hepatocellular carcinoma(HCC) cells remains unknown.METHODS:Expression of 12-LOX was assessed in a diethylnitrosamine-induced rat HCC model,and in SMMC-7721,HepG2 and L-02 cells using immunohistochemical staining and reverse transcriptase-polymerase chain reaction(RT-PCR).GST-π and Ki-67 were determined in vivo by immunohistochemical staining.Apoptosis was evaluated by TUNEL assay.Cell viability and apoptosis were determined by MTT assay and flow cytometry,respectively.Apoptosis-related proteins in SMMC-7721 and HepG2 cells were detected by Western blotting.RESULTS:Immunohistochemical staining and RT-PCR showed that 12-LOX was over-expressed in rat HCC and two HCC cell lines,while the expression was inhibited by baicalein,a specific inhibitor of 12-LOX.Baicalein inhibited cell proliferation and induced apoptosis in rat HCC and both cell lines in a dose-and time-dependent manner.Our in vivo study demonstrated that baicalein also reduced neoplastic nodules.Mechanistically,baicalein reduced Bcl-2 protein expression coupled with a slight increase of the expression of Bax and activation of caspase-3.Furthermore,baicalein inhibited the activation of ERK-1/2(phosphorylated).Interestingly,the effects of baicalein were reversed by 12(S)-HETE,a metabolite of 12-LOX.CONCLUSIONS:Inhibition of 12-LOX leads to reduced numbers of HCC cells,partially caused by increased apoptosis.12-LOX may be a potential molecular target for HCC prevention and treatment. | Xi-Ming Xu,Guang-Jin Yuan,Jun-Jian Deng,Hong-Ting Guo,Miao Xiang,Fang Yang,Wei Ge and Shi-You Chen Cancer Center, Renmin Hospital of Wuhan University, Wuhan 430060, China Cancer Center, the 82nd Hospital of the Chinese PLA, Huai’an 223001, China Department of Physiology, Medical College of Wuhan University, Wuhan 430071, China Department of Physiology & Pharmacology, University of Georgia, Athens, GA 30602, USA | 2012 | Hepatobiliary & Pancreatic Diseases International2012，11，2： | 20 |
| 3 | Management of patients after recovering from acute severe biliary pancreatitis显示文摘Cholelithiasis is the most common cause of acute pancreatitis,accounting 35%-60% of cases. Around 15%-20% of patients suffer a severe attack with high morbidity and mortality rates. As far as treatment is concerned,the optimum method of late management of patients with severe acute biliary pancreatitis is still contentious and the main question is over the correct timing of every intervention. Patients after recovering from an acute episode of severe biliary pancreatitis can be offered alternative options in their management,including cholecystectomy,endoscopic retrograde cholangiopancreatography(ERCP) and sphincterotomy,or no definitive treatment. Delaying cholecystectomy until after resolution of the inflammatory process,usually not earlier than 6 wk after onset of acute pancreatitis,seems to be a safe policy. ERCP and sphincterotomy on index admission prevent recurrent episodes of pancreatitis until cholecystectomy is performed,but if used for definitive treatment,they can be a valuable tool for patients unfit for surgery. Some patients who survive severe biliary pancreatitis may develop pseudocysts or walled-off necrosis. Management of pseudocysts with minimally invasive techniques,if not therapeutic,can be used as a bridge to definitive operative treatment,which includes delayed cholecystectomy and concurrent pseudocyst drainage in some patients. A management algorithm has been developed for patients surviving severe biliary pancreatitis according to the currently published data in the literature. | Georgia Dedemadi Manolis Nikolopoulos Ioannis Kalaitzopoulos George Sgourakis | 2016 | World Journal of Gastroenterology2016，22，34： | 20 |
| 4 | Impact of periampullary diverticula on the outcome and fluoroscopy time in endoscopic retrograde cholangiopancreatography显示文摘BACKGROUND: It is unclear whether the presence of periampullary diverticula (PAD) affects technical success and complication rates during endoscopic retrograde cholangio- pancreatography (ERCP). Moreover, the impact of PAD on fluoroscopy duration is still unknown. The present study aimed to investigate the success rate and difficulty of common bile duct (CBD) cannulation, post-procedure complications and fluoroscopy duration in patients with and without PAD. METHODS: Patients from January 2008 to December 2010 with PAD (group A) and without PAD (group B) and similar indications for therapeutic ERCP were prospectively compared. The comparison included patient characteristics, findings of ERCP, and details of procedure and fluoroscopy time. The influence of papilla's location with respect to the diverticulum on procedure was also investigated. RESULTS: A total of 428 consecutive patients who had undergone therapeutic ERCP for similar indications were divided in two groups according to the presence (group A, 107 patients) or absence (group B, 321 patients) of PAD. The mean age and ASA score of the patients with PAD were significantly higher than those patients without PAD. The main indication was choledocholithiasis. Successful final CBD cannulation was achieved in 97.20% of the patients in group A vs 99.69% in group B (P=0.05). CBD diameter, number of stones and the largest stone size were significantly higher in group A thangroup B (P<0.001). Complete clearance of the CBD after the first attempt was achieved in 85.86% and 94.75% of the patients in groups A and B, respectively (P=0.03). In both groups, the time needed to complete the procedure and fluoroscopy time was significantly longer in patients with PAD (22.87 vs 18.99 minutes, P<0.001; 76.51 vs 47.42 seconds, P<0.001). There was no significant difference between the two groups in the complication rate. The type of papilla's location with respect to the diverticulum did not influence the total cannulation rate and post-procedure complications. CONCLUSION: The presence of a PAD does not affect the success rate and complications of therapeutic ERCP in expert hands; however, the fluoroscopy time is significantly longer in patients with PAD. | Panagiotis Katsinelos Grigoris Chatzimavroudis Kostas Tziomalos Christos Zavos Athanasios Beltsis Georgia Lazaraki Sotiris Terzoudis Jannis Kountouras | 2013 | Hepatobiliary & Pancreatic Diseases International2013，12，4： | 15 |
| 5 | 系统综述与网状Meta分析的PRISMA扩展声明显示文摘PRISMA声明旨在提高系统综述和META分析报告的完整性,该声明已经广泛用于指导系统综述和META分析的报告和发表。原始的PRISMA声明是针对两种干预措施比较的传统的系统综述与META分析而制定的,然而,随着多种干预措施比较的系统综述的发展,实施和报告这一类系统综述面临较大挑战。此时,针对网状META分析的PRISMA扩展声明应运而生,旨在提高网状META分析系统综述的报告质量。PRISMA扩展声明是由专家们通过DELPHI调查、面对面讨论和共识大会而最终确立的。PRISMA扩展声明是在原始PRISMA声明的报告清单的基础上经过修改,最终确定了32个条目,每个条目均与网状META分析报告的内容直接相关。本文对网状META分析的PRISMA扩展声明进行了阐述,对报告清单各条目进行了举例说明,并详细说明了在原始PRISMA声明的基础上新增和修改各条目的理由。此外,PRISMA扩展声明强调了在网状META分析的实际操作中需要重点关注的信息。本文的目标读者包括网状META分析的作者与读者,以及期刊杂志的编辑与同行评审。 | 李志霞 杨俊 叶欣 周凌波 杨智荣 孙凤 詹思延 Brian Hutton Georgia Salanti Deborah M.Caldwell Anna Chaimani Christopher H.Schmid Chris Cameron John P.A.Ioannidis Sharon Straus Kristian Thorlund Jeroen P.Jansen Cynthia Mulrow Ferrán Catalá-López Peter C.Gozsche Kay Dickersin Isabelle Boutron Douglas G.Altman David Moher | 2016 | 中国循证心血管医学杂志2016，8，6： | 11 |
| 6 | Thrombosis and inflammatory bowel disease-the role of genetic risk factors显示文摘Thromboembolism is a significant cause of morbidity and mortality in patients with inflammatory bowel dis-ease (IBD). Recent data suggest thromboembolism as a disease-specific extraintestinal manifestation of IBD, which is developed as the result of multiple interac- tions between acquired and genetic risk factors. There is evidence indicating an imbalance of procoagulant, anticoagulant and fibrinolitic factors predisposing in thrombosis in patients with IBD. The genetic factors that have been suggested to interfere in the thrombotic manifestations of IBD include factor Leiden, factor (prothrombin, G20210A), methylenetetrahydrofolate reductase gene mutation (MTHFR, 6777T), plasminogen activator inhibitor type 1 (PAI-1) gene mutation and fac- tor (val34leu). In this article we review the current data and future prospects on the role of genetic risk factors in the development of thromboembolism in IBD. | Georgia Tsiolakidou Ioannis E Koutroubakis | 2008 | World Journal of Gastroenterology2008，14，28： | 9 |
| 7 | Multimode optical fiber transmission with a deep learning network显示文摘Multimode fibers(MMFs)are an example of a highly scattering medium,which scramble the coherent light propagating within them to produce seemingly random patterns.Thus,for applications such as imaging and image projection through an MMF,careful measurements of the relationship between the inputs and outputs of the fiber are required.We show,as a proof of concept,that a deep neural network can learn the input-output relationship in a 0.75 m long MMF.Specifically,we demonstrate that a deep convolutional neural network(CNN)can learn the nonlinear relationships between the amplitude of the speckle pattern(phase information lost)obtained at the output of the fiber and the phase or the amplitude at the input of the fiber.Effectively,the network performs a nonlinear inversion task.We obtained image fidelities(correlations)as high as~98%for reconstruction and~94%for image projection in the MMF compared with the image recovered using the full knowledge of the system transmission characterized with the complex measured matrix.We further show that the network can be trained for transfer learning,i.e.,it can transmit images through the MMF,which belongs to another class not used for training/testing. | Babak Rahmani Damien Loterie Georgia Konstantinou Demetri Psaltis Christophe Moser | 2018 | Light(Science & Applications)2018，7，1： | 9 |
| 8 | Glutamate transporters, EAAT1 and EAAT2, are potentially important in the pathophysiology and treatment of schizophrenia and affective disorders显示文摘Glutamate is the predominant excitatory neurotransmitter in the human brain and it has been shown that prolonged activation of the glutamatergic system leads to nerve damage and cell death. Following release from the pre-synaptic neuron and synaptic transmission, glutamate is either taken up into the presynaptic neuron or neighbouring glia by transmembrane glutamate transporters. Excitatory amino acid transporter(EAAT) 1 and EAAT2 are Na+-dependant glutamate transporters expressed predominantly in glia cells of the central nervous system. As the most abundant glutamate transporters, their primary role is to modulate levels of glutamatergic excitability and prevent spill over of glutamate beyond the synapse. This role is facilitated through the binding and transportation of glutamate into astrocytes and microglia. The function of EAAT1 and EAAT2 is heavily regulated at the levels of gene expression, post-transcriptional splicing, glycosylation states and cell-surface trafficking of the protein. Both glutamatergic dysfunction and glial dysfunction have been proposed to be involved in psychiatric disorder. This review will present an overview of the roles that EAAT1 and EAAT2 play in modulating glutamatergic activity in the human brain, and mount an argument that these two transporters could be involved in the aetiologies of schizophrenia and affective disorders as well as represent potential drug targets for novel therapies for those disorders. | Georgia M Parkin Madhara Udawela Andrew Gibbons Brian Dean | 2018 | World Journal of Psychiatry2018，8，2： | 9 |
| 9 | In-plane bistatic backward scattering from seabottom with randomly inhomogeneous sediment and rough interface显示文摘The in-plane bistatic backward scattering caused by seabottom with random inhomogeneities and rough interface is studied. This work combines the ray tube integral method of Ivakin et al. and the complex-ray/steepest descent method of Hines. For a given incident grazing angle, the theoretical expression can easily be used to calculate scattering strength for different backward scattering angles. (This is essential for modeling shallow water reverberation by the normal mode approach.) The model is tested against published scattering measurements. The frequency/angle dependence of backward scattering and effects of volume inhomogeneity parameters on backward scattering are also discussed. | PENG Zhaohui1,,ZHOU Jixun1,& ZHANG Renhe1 2 2 1.Institute of Acoustics,Chinese Academy of Sciences,Beijing 100080,China 2.School of Mechanical Engineering,Georgia Institute of Technology,Atlanta,GA 30332,USA | 2004 | Science China(Physics,Mechanics & Astronomy)2004，47，6： | 8 |
| 10 | Biomarkers in the clinical management of patients with atrial fibrillation and heart failure显示文摘Atrial fibrillation(AF)and heart failure(HF)are two cardiovascular diseases with an increasing prevalence worldwide.These conditions share common pathophysiologiesand frequently co-exit.In fact,the occurrence of either condition can‘cause’the development of the other,creating a new patient group that demands different management strategies to that if they occur in isolation.Regardless of the temproral association of the two conditions,their presence is linked with adverse cardi-ovascular outcomes,increased rate of hospitalizations,and increased economic burden on healthcare systems.The use of low-cost,easily accessible and applicable biomarkers may hasten the correct diagnosis and the effective treatment of AF and HF.Both AF and HF effect multiple physiological pathways and thus a great number of biomarkers can be measured that potentially give the clinician important diagnostic and prognostic information.These will then guide patient centred therapeutic management.The current biomarkers that offer potential for guiding therapy,focus on the physiological pathways of miRNA,myocardial stretch and injury,oxidative stress,inflammation,fibrosis,coagulation and renal impairment.Each of these has different utility in current clinincal practice. | Ioanna Koniari Eleni Artopoulou Dimitrios Velissaris Mark Ainslie Virginia Mplani Georgia Karavasili Nicholas Kounis Grigorios Tsigkas | 2021 | Journal of Geriatric Cardiology2021，18，11： | 8 |
| 11 | Primary gastric melanoma: A case report显示文摘为所有恶性瘤的 1-3% 的黑瘤报道。除了皮肤,另外的不太普通的黑瘤包括在其它之中,那些在官方补给的道。然而,他们的主要或第二等的性质经常是困难的建立。指胃,主要黑瘤的散布案例在文学被报导了。我们在胃的窦与一个溃烂的 sub-mucosal 团报导一个人的一个案例,迟钝的上面的腹的疼痛地表明了,恶心,呕吐,疲劳和贫血症。这损害组织学地被证明是黑瘤。临床的详细说明的 A 和实验室调查没在其它地方揭示主要地点。到我们的知识,主要胃的黑瘤的很少的案例被报导了。我们的案例是第四曾经出版了,第一在胃的窦定位了。在如此的损害的原始性质之上的争论仍然坚持。因此,特定的诊断标准被建议了。 | Emmanuel Eustathios Lagoudianakis Michael Genetzakis Dimitrios Konstantinos Tsekouras Artemisia Papadima Georgia Kafiri Konstantinos Toutouzas Vaggelogiannis Katergiannakis Andreas Manouras | 2006 | World Journal of Gastroenterology2006，12，27： | 8 |
| 12 | Primary biliary cirrhosis in HBV and HCV patients:Clinical characteristics and outcome显示文摘AIM: To present the characteristics, management and outcome of patients with hepatitis B virus(HBV) or hepatitis C virus(HCV) infections concurrent with primary biliary cirrhosis(PBC).METHODS: Since January 2001 to September 2009,we retrospectively evaluated the medical records of all HBV(n = 1493) and HCV patients(n = 526) who are followed in our center for the presence of concurrent PBC. Seventeen patients identified with concurrent viral hepatitis and PBC(8 HCV and PBC; follow-up: 61 ± 37 mo and 9 HBV and PBC; follow-up: 57 ± 38 mo). PBC diagnosis was established if the patients met at least two of the following criteria: positivity for antimitochondrial antibody, elevated cholestatic enzymes and histological lesions of PBC.RESULTS: HCV or HBV diagnosis preceded that of PBC in most patients by many years. PBC diagnosis was based on the presence of antimitochondrial antibody and elevated cholestatic enzymes in all 17 patients,while one third(5/17; 29.4%) experienced severe pruritus many years before diagnosis. Patients with PBC and HBV were significantly younger at diagnosis of PBC compared to patients with PBC and HCV(56.1 ± 11.2vs 68.5 ± 10.3, respectively, P < 0.05). At initial clinical and histological assessment the majority of patients were cirrhotics(10/17; 58.8%) with the group of PBC and HCV carrying the highest frequency(87.5% vs33.3% in PBC and HBV; P < 0.05). The patients with HBV and concomitant PBC seem to have better outcome compared to those with HCV and PBC since none of the 6 non-cirrhotics with HBV and PBC developed cirrhosis during follow-up.CONCLUSION: PBC diagnosis in HBV or HCV patients is very difficult and usually delayed. Therefore, in any case, cholestasis should alert physicians to further search for PBC. | Eirini I Rigopoulou Kalliopi Zachou Nikolaos K Gatselis Georgia Papadamou George K Koukoulis George N Dalekos | 2013 | World Journal of Hepatology2013，5，10： | 7 |
| 13 | Post-partum reactivation of chronic hepatitis B virus infection among hepatitis B e-antigen-negative women显示文摘AIM: To investigate the frequency and timing of post-partum chronic hepatitis B virus(HBV) reactivation and identify its pre-partum predictors. METHODS: Forty-one hepatitis B e antigen(HBe Ag)-negative chronic HBV infected pregnant women were prospectively evaluated between the 28 th and the 32 nd week of gestation. Subjects were re-evaluated at 3-mo intervals during the first post-partum year and every 6 mo during the following years. HBV DNA was determined using real-time reverse transcription polymerase chain reaction(Cobas Taq Man HBV Test) with a lower detection limit of 8 IU/m L. Post-partum reactivation(PPR) was defined as abnormal alanine aminotransaminase(ALT) levels and HBV DNA above 2000 IU/m L. RESULTS: Fourteen out of 41 women(34.1%) had prepartum HBV DNA levels > 2000 IU/m L, 18(43.9%) had levels < 2000 IU/m L and 9(21.9%) had undetectable levels. Fourteen women were lost to follow-up(failure to return). PPR occurred in 8 of the 27(29.6%) women evaluated, all within the first 6 mo after delivery(5 at month 3; 3 at month 6). Five of the 6(83.3%) women with pre-partum HBV DNA > 10000 IU/m L exhibited PPR compared with 3 of the 21(14.3%) women with HBV DNA < 10000 IU/m L(two with HBV DNA > 2000 and the third with HBV DNA of 1850IU/m L), P = 0.004. An HBV DNA level ≥ 10000 IU/m L independently predicted post-partum HBV infection reactivation(OR = 57.02, P = 0.033). Mean pre-partum ALT levels presented a non-significant increase in PPR cases(47.3 IU/L vs 22.2 IU/L, respectively, P = 0.094).CONCLUSION: In the present study, PPR occurred in approximately 30% of HBe Ag-negative pregnant women; all events were observed during the first semester after delivery. Pre-partum HBV DNA level > 10000 IU/m L predicted PPR. | Ioannis Elefsiniotis Elena Vezali Dimitrios Vrachatis Sofia Hatzianastasiou Stefanos Pappas George Farmakidis Georgia Vrioni Athanasios Tsakris | 2015 | World Journal of Gastroenterology2015，21，4： | 7 |
| 14 | Corticosteroid-free immunosuppression in liver transplantation: An evidence-based review显示文摘Thirty-six randomized controlled trials and two metaanalyses were reviewed. With respect to adult patients undergoing first orthotopic liver transplantation(OLT), steroid replacement resulted in fewer cases of overall acute rejection in the corticosteroid free-immunosuppression arm. Initial steroid administration for two weeks and early tacrolimus monotherapy is a feasible immunosuppression regimen without steroid replacement, although further investigations are needed in view of chronic rejections. No significant differences were noted between the treatment groups in terms of patient and graft survival independently of steroid replacement. Renal insufficiency, de novo hypertension, neurological disorders and infectious complications did not differ significantly among steroid and steroidfree groups. Diabetes mellitus, cholesterol levels and cytomegalovirus infection are more frequent in patients within the steroid group. With respect to diabetes mellitus and hypercholesterolemia, the difference was independent of steroid replacement. In relation to transplanted hepatitis C virus patients, mycophenolate mofetil does not appear to have a significant antiviral effect despite early reports. Male gender of donors and recipients, living donors, cold ischemia times, acute rejection, and early histological recurrence were related to the development of advanced hepatitis. There is sufficient scientific clinical evidence advocating avoidance of the ab initio use of steroids in OLT. | George Sgourakis Georgia Dedemadi | 2014 | World Journal of Gastroenterology2014，20，31： | 6 |
| 15 | Transanal polypectomy using single incision laparoscopic instruments显示文摘Transanal excision of rectal polyps with laparoscopic instrumentation and a single incision laparoscopic port is a novel technique that uses technology originally developed for abdominal procedures from the natural orifice of the rectum. Transanal endoscopic microsurgery (TEM) is a well established surgical approach for certain benign or early malignant lesions of the rectum, under specific indications. Our technique is a hybrid technique of transanal surgery, a reasonable method for polyp resection without the need of the sophisticated and expensive instrumentation of TEM which can be applied whenever endoscopic or conventional transanal surgical removal is not feasible. | Dimitrios Dardamanis Dimitrios Theodorou George Theodoropoulos Andreas Larentzakis Maria Natoudi Georgia Doulami Christina Zoumpouli Haridimos Markogiannakis Stylianos Katsaragakis George C Zografos | 2011 | World Journal of Gastrointestinal Surgery2011，3，4： | 6 |
| 16 | TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer显示文摘BACKGROUND Patients with stage II-III colorectal cancer (CRC) treated with adjuvant chemotherapy, gain a 25% survival benefit. In the context of personalized medicine, there is a need to identify patients with CRC who may benefit from adjuvant chemotherapy. Molecular profiling could guide treatment decisions in these patients. Thymidylate synthase (TYMS) gene polymorphisms, KRAS and BRAF could be included in the molecular profile under consideration. AIM To investigate the association of TYMS gene polymorphisms, KRAS and BRAF mutations with survival of CRC patients treated with chemotherapy.METHODS A retrospective study studied formalin-fixed paraffin-embedded tissues (FFPEs) of consecutive patients treated with adjuvant chemotherapy during January/2005-January/2007. FFPEs were analysed with PCR for the detection of TYMS polymorphisms, mutated KRAS (mKRAS) and BRAF (mBRAF). Patients were classified into three groups (high, medium and low risk) according to 5’UTR TYMS polymorphisms Similarly, based on 3’UTR polymorphism ins/loss of heterozygosity (LOH) patients were allocated into two groups (high and low risk of relapse, respectively). Cox regression models examined the associated 5- year survival outcomes. RESULTS One hundred and thirty patients with early stage CRC (stage I-II: 55 patients;stage III 75 patients;colon: 70 patients;rectal: 60 patients) were treated with surgery and chemotherapy. The 5-year disease free survival and overall survival rate was 61.6% and 73.9% respectively. 5’UTR polymorphisms of intermediate TYMS polymorphisms (2RG/3RG, 2RG/LOH, 3RC/LOH) were associated with lower risk for relapse [hazard ratio (HR) 0.320, P = 0.02 and HR 0.343, P = 0.013 respectively] and death (HR 0.368, P = 0.031 and HR 0.394, P = 0.029 respectively). The 3’UTR polymorphism ins/LOH was independently associated with increased risk for disease recurrence (P = 0.001) and death (P = 0.005). mBRAF (3.8% of patients) was associated with increased risk of death (HR 4.500, P = 0.022) whereas mKRAS (39% of patients) not. CONCLUSION Prospective validating studies are required to confirm whether 2RG/3RG, 2RG/LOH, 3RC/LOH, absence of ins/LOH and wild type BRAF may indicate patients at lower risk of relapse following adjuvant chemotherapy. | Anastasios Ntavatzikos Aris Spathis Paul Patapis Nikolaos Machairas Georgia Vourli George Peros Iordanis Papadopoulos Ioannis Panayiotides Anna Koumarianou | 2019 | World Journal of Gastrointestinal Oncology2019，11，7： | 5 |
| 17 | Effects of salinity on methane gas hydrate system显示文摘Using an approximately analytical formation, we extend the steady state model of the pure methane hydrate system to include the salinity based on the dynamic model of the methane hydrate system. The top and bottom boundaries of the methane hydrate stability zone (MHSZ) and the actual methane hy-drate zone (MHZ), and the top of free gas occurrence are determined by using numerical methods and the new steady state model developed in this paper. Numerical results show that the MHZ thickness becomes thinner with increasing the salinity, and the stability is lowered and the base of the MHSZ is shifted toward the seafloor in the presence of salts. As a result, the thickness of actual hydrate occur-rence becomes thinner compared with that of the pure water case. On the other hand, since lower solubility reduces the amount of gas needed to form methane hydrate, the existence of salts in sea-water can actually promote methane gas hydrate formation in the hydrate stability zone. Numerical modeling also demonstrates that for the salt-water case the presence of methane within the field of methane hydrate stability is not sufficient to ensure the occurrence of gas hydrate, which can only form when the methane concentration dissolved in solution with salts exceeds the local methane solubility in salt water and if the methane flux exceeds a critical value corresponding to the rate of diffusive methane transport. In order to maintain gas hydrate or to form methane gas hydrate in marine sedi-ments, a persistent supplied methane probably from biogenic or thermogenic processes, is required to overcome losses due to diffusion and advection. | YANG DingHui1 & XU WenYue2 1 Department of Mathematical Sciences, Tsinghua University, Beijing 100084, China 2 School of Earth & Atmospheric Sciences, Georgia Institute of Technology, Atlanta, GA 30332, USA | 2007 | Science China Earth Sciences2007，50，11： | 5 |
| 18 | Potential implications of Helicobacter pylori-related neutrophil-activating protein显示文摘Helicobacter pylori (H.pylori) virulence factors promote the release of various chemoattractants/inflammatory mediators,including mainly the neutrophilattractant chemokine interleukin-8 and neutrophilactivating protein (NAP),involved in H.pylori-induced gastric pathologies.Co-administration of Chios mastic gum (CMG),which inhibits H.pylori NAP,with an H.pylori eradication regimen might add clinical benefits against H.pylori-related gastric pathologies,but possibly not CMG as main therapy.Although H.pylori NAP and other H.pylori-related cytotoxins [i.e.,vaculating cytotoxin (VacA)] appear to play a major role in generating and maintaining the H.pylori-associated gastric inflammatory response and H.pylori NAP is a promising vaccine candidate against H.pylori infection (H.pylori-I),concerns regarding its potential drawbacks,particularly neurogenic ones,due to possible crossmimicry,should be considered.Possible cross-mimicry between H.pylori NAP and/or bacterial aquaporin (AQP) and neural tissues may be associated with the anti-AQP-4 antibody-related neural damage in multiple sclerosis (MS)/neuromyelitis optica patients.Moreover,the sequence homology found between H.pylori VacA and human Na+/K+-ATPase A subunit suggests that antibodies to VacA involve ion channels in abaxonal Schwann cell plasmalemma resulting in demyelination in some patients.A series of factors have been implicated in inducing blood-brain barrier (BBB) disruption,including inflammatory mediators (e.g.,cytokines and chemokines induced by H.pylori-I) and oxidative stress.BBB disruption permits access of AQP4-specific antibodies and T lymphocytes to the central nervous system,thereby playing a major role in multiple sclerosis pathogenesis.Relative studies show a strong association between H.pylori-I and MS.H.pylori-I induces humoral and cellular immune responses that,owing to the sharing of homologous epitopes (molecular mimicry),cross-react with components of nerves,thereby contributing and perpetuating neural tissue damage.Finally,H.pylori NAP also plays a possible pathogenetic role in both gastric and colon oncogenesis. | Jannis Kountouras Christos Zavos Georgia Deretzi Emmanuel Gavalas Dimitrios Chatzopoulos Panagiotis Katsinelos Elena Tsiaousi Stergios Gagalis Stergios A Polyzos Ioannis Venizelos | 2012 | World Journal of Gastroenterology2012，18，5： | 5 |
| 19 | Stimulating erythropoiesis in inflammatory bowel disease associated anemia显示文摘Anemia is a frequent complication in patients with inflammatory bowel disease (IBD), and is associated with decreased quality of life and increased rate of hospitalization. The primary therapeutic targets of IBD- associated anemia are iron deficiency and anemia of chronic disease. An important prognostic parameter of the success or failure of therapy is the outcome of the underlying disease. Iron deficiency should be appropriately managed with iron supplementation. However, the use of oral iron therapy is limited by several problems, the most important being gastrointestinal side effects leading occasionally to disease relapse and poor iron absorption. Intravenous iron preparations are more reliable, with iron sucrose demonstrating the best efficacy and tolerability. Treatment with erythropoietin or darbepoetin has been proven to be effective in patients with anemia, who fail to respond to intravenous iron. Patients with ongoing inflammation have anemia of chronic disease and may require combination therapy comprising of intravenous iron sucrose and erythropoietin. After initiating treatment, careful monitoring of hemoglobin levels and iron parameters is needed in order to avoid recurrence of anemia. In conclusion, anemia in the setting of IBD should be aggressively diagnosed, investigated, and treated. Future studies should define the optimal dose and schedule of intravenous iron supplementation and appropriate erythropoietin therapy in these patients. | Georgia Tsiolakidou Ioannis E Koutroubakis | 2007 | World Journal of Gastroenterology2007，13，36： | 5 |
| 20 | Recent advances in pharmacological treatment of irritable bowel syndrome显示文摘Irritable bowel syndrome(IBS) is a highly prevalent functional disorder that reduces patients' quality of life. It is a chronic disorder characterized by abdominal pain or discomfort associated with disordered defecation in the absence of identifiable structural or biochemical abnormalities. IBS imposes a significant economic burden to the healthcare system. Alteration in neurohumoral mechanisms and psychological factors, bacterial overgrowth, genetic factors, gut motility, visceral hypersensitivity, and immune system factors are currently believed to influence the pathogenesis of IBS. It is possible that there is an interaction of one or more of these etiologic factors leading to heterogeneous symptoms of IBS. IBS treatment is predicated upon the patient's most bothersome symptoms. Despite the wide range of medications and the high prevalence of the disease, to date no completely effective remedy is available. This article reviews the literature from January 2008 to July 2013 on the subject of IBS peripherally acting pharmacological treatment. Drugs are categorized according to their administration for IBS-C, IBS-D or abdominal pain predominant IBS. | Georgia Lazaraki Grigoris Chatzimavroudis Panagiotis Katsinelos | 2014 | World Journal of Gastroenterology2014，20，27： | 5 |
您所在的机构暂未开通此部分的功能，请联系管理员